COSUDEX® 50 mg tablets
bicalutamide

PRODUCT INFORMATION

NAME OF THE MEDICINE

BICALUTAMIDE.

Chemical Name: (RS)-4'-Cyano-α’, α’, α’', trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide.

Structural Formula:

![Structural Formula](image)

CAS Number: 90357-06-5.
Molecular formula: C₁₈H₁₄F₄N₂O₄S
Molecular weight: 430.38

DESCRIPTION

Bicalutamide is a fine white to off-white powder. At 37°C it is practically insoluble in water (4.6 mg/litre), acid (4.6 mg/litre at pH 1) and alkali (3.7 mg/litre at pH 8). In organic solvents it is slightly soluble in ethanol, sparingly soluble in methanol and freely soluble in acetone and tetrahydrofuran.

COSUDEX 50 mg tablets are white film coated tablets containing 50 mg bicalutamide. Each tablet contains the following excipients: lactose, sodium starch glycollate, povidone, magnesium stearate, hypromellose, macrogol 300 and titanium dioxide.

PHARMACOLOGY

Bicalutamide is a non-steroidal anti-androgen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. This inhibition impairs the growth and encourages apoptosis in androgen-dependent tumour cells and regression of prostatic tumours. In a subset of patients who experience disease progression while
receiving bicalutamide, discontinuation of the drug may result in an ‘anti-androgen withdrawal syndrome’, which manifests as a fall in prostate specific antigen (PSA) level. It is unknown whether this phenomenon translates to a prolongation of tumour response or survival.

Bicalutamide is a racemate with its anti-androgenic activity being almost exclusively in the (R)-enantiomer.

**Pharmacokinetics**

**Absorption**

COSUDEX is well absorbed following oral administration. There is no evidence of any clinically relevant effect of food on bioavailability.

**Distribution**

Bicalutamide is highly protein bound (racemate 96%, R-enantiomer 99.6%).

Steady state plasma concentrations of the (R)-enantiomer of approximately 9 μg per mL are observed during daily administration of COSUDEX 50 mg. At steady state the predominantly active (R)-enantiomer accounts for 99% of the total circulating enantiomers.

**Metabolism and Elimination**

Bicalutamide undergoes stereospecific metabolism. Bicalutamide is extensively metabolised (via oxidation and glucuronidation). Its metabolites are eliminated via the kidneys and bile in approximately equal proportions.

The (S)-enantiomer is rapidly cleared relative to the (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week. On daily administration of COSUDEX, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long half-life.

The pharmacokinetics of the (R)-enantiomer are unaffected by age, renal impairment or mild to moderate hepatic impairment. There is evidence that for subjects with severe hepatic impairment, the (R)-enantiomer is more slowly eliminated from plasma.

**CLINICAL TRIALS**

**Combination therapy (with medical castration) in advanced prostate cancer**

In a large multicentre, controlled clinical trial, 813 patients with previously untreated advanced prostate cancer were randomized to receive COSUDEX 50 mg once daily (404 patients) or flutamide 250 mg (409 patients) three times a day, each in combination with a Luteinising Hormone Releasing (LHRH) (either goserelin acetate implant or leuprorelin acetate depot). At the time of analysis, the median time of follow-up was 49 weeks. COSUDEX/LHRH agonist therapy was associated with a statistically significant (p=0.005) improvement in time to treatment failure.
Subjective responses, (including scores for pain, analgesic use and Eastern Oncology Cooperative Group (ECOG) performance status) assessed in patients with symptoms at entry were seen in 95 (52%) patients treated with COSUDEX and in 88 (54%) patients treated with flutamide, each in combination therapy with LHRH agonists. This small difference was not statistically significant between COSUDEX 50 mg combination therapy and flutamide combination therapy.

Meta-Analysis

There is considerable debate regarding the relative merits of combination versus monotherapy in advanced prostate cancer, summarised by Dalesio et al 1995¹ in their meta-analysis of trials of maximal androgen blockade (MAB). This analysis showed no statistically significant reduction in the annual odds of death in favour of MAB. The meta-analysis included the effect of MAB only on mortality, and did not measure other end-points such as time to disease progression.

INDICATIONS

Treatment of advanced prostate cancer in combination with LHRH agonist therapy.

Prevention of disease flare associated with the use of LHRH agonists.

CONTRAINDICATIONS

COSUDEX is contraindicated in females and children.

Known hypersensitivity to bicalutamide or any other constituents of the formulation.

Co-administration of terfenadine, astemizole or cisapride with COSUDEX is contraindicated (see Interactions with other Medicines).

PRECAUTIONS

Bicalutamide is extensively metabolised in the liver. Data suggests that its elimination may be slower in subjects with severe hepatic impairment and this could lead to increased accumulation of bicalutamide. Therefore, COSUDEX should be used with caution in patients with moderate to severe hepatic impairment.

Periodic liver function testing should be considered due to the possibility of hepatic changes. The majority of these changes occur within the first 6 months of COSUDEX therapy.

Rare cases of death or hospitalisation due to severe liver injury have been observed with COSUDEX (see ADVERSE EFFECTS). COSUDEX therapy should

---

be discontinued if at any time a patient develops jaundice or if serum ALT rises above two times the upper limit of normal.

A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycaemic control in those with pre-existing diabetes. Consideration should therefore be given to monitoring blood glucose in patients receiving COSUDEX in combination with LHRH agonists.

In patients with metastatic prostate cancer, treatment with bicalutamide monotherapy has been associated with reduced survival compared to castration. COSUDEX should therefore not be used without concomitant LHRH agonist therapy in these patients.

**Carcinogenicity/Genotoxicity**

Bicalutamide was inactive in *in vitro* tests for gene mutation and in *in vitro* and *in vivo* tests for clastogenicity.

Two-year oral carcinogenicity studies were conducted in male and female rats and mice at doses of 5, 15 or 75 mg/kg/day of bicalutamide. A variety of tumour target organ effects were identified and were attributed to the antiandrogenicity of bicalutamide, namely, testicular benign interstitial (Leydig) cell tumours in male rats at all dose levels and uterine adenocarcinoma in female rats at 75 mg/kg/day (at these dose levels plasma (R)-bicalutamide concentrations were less than human therapeutic concentrations after the maximum recommended clinical dose of 150 mg). There is no evidence of Leydig cell hyperplasia in patients; uterine tumours are not relevant to the indicated patient population.

A small increase in the incidence of hepatocellular carcinoma in male mice given 75 mg/kg/day of bicalutamide (approximately 2 times human therapeutic concentrations after the maximum recommended clinical dose of 150 mg) and an increased incidence of benign thyroid follicular cell adenomas in rats given 5 mg/kg/day (less than the human therapeutic concentrations after the maximum recommended clinical dose of 150 mg) and above were recorded. These neoplastic changes were progressions of non-neoplastic changes related to hepatic enzyme induction observed in animal toxicity studies. Enzyme induction has not been observed following bicalutamide administration in man.

**Effects on fertility**

Administration of bicalutamide may lead to inhibition of spermatogenesis. The long-term effects of bicalutamide on male fertility have not been studied. In male rats dosed at 250 mg/kg/day (less than human therapeutic concentrations after the maximum recommended clinical dose of 150 mg), the precoital interval and time to successful mating were increased in the first pairing but no effects on fertility following successful mating were seen. These effects were reversed by 7 weeks after the end of an 11-week period of dosing.

**Use in pregnancy – Category D**

COSUDEX is contraindicated in females and must not be given to pregnant women.
Use in lactation
COSUDEX is contraindicated in females and must not be given to breast-feeding mothers.

Interactions with other medicines
COSUDEX is extensively metabolised (via oxidation and glucuronidation) in the liver. COSUDEX has shown no evidence of causing enzyme induction in humans during dosing at 50 mg daily in man. In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.

The clinically or potentially significant drug interactions between COSUDEX and the following agents/drug classes, which are theoretical or have been observed, are described below. The drug/drug interactions described include both interactions mediated through effects on P450 metabolism and interactions mediated through other mechanisms.

Effects of bicalutamide on other medicines
LHRH agonists: Although there is no evidence of any pharmacodynamic or pharmacokinetic interactions between COSUDEX 50mg and LHRH agonists at steady state, COSUDEX 50mg may prevent the harmful clinical consequences of flare associated with the start of LHRH agonist therapy.

Cytochrome P450: Bicalutamide is an inhibitor of CYP 3A4 and has been shown to increase plasma levels of midazolam by up to 80%. Therefore, concomitant use of terfenadine, astemizole and cisapride is contraindicated. Caution should be exercised with other drugs metabolised by CYP 3A4, such as cyclosporin, calcium channel blockers, HIV antivirals, HMGCoA reductase inhibitors, carbamazepine, quinidine etc.

Demonstrated interactions
Warfarin: In vitro studies have shown that bicalutamide can displace the coumarin anticoagulant, warfarin, from its protein binding sites. It is therefore recommended that if COSUDEX is started in patients who are already receiving coumarin anticoagulants, prothrombin time should be closely monitored.

Theoretical interactions
Caution should be exercised when prescribing COSUDEX with other drugs which may inhibit drug oxidation eg. cimetidine and ketoconazole. In theory, this could result in increased plasma concentrations of bicalutamide and an increase in adverse reactions.

Effects on ability to drive and use machines
During treatment with COSUDEX, somnolence has been reported. Those patients who experience this symptom should observe caution when driving or using machines.
ADVERSE EFFECTS

COSUDEX 50 mg in general, has been well tolerated with few withdrawals due to adverse events.

Clinical trial data - Combination therapy (with medical castration) in advanced prostate cancer

The following adverse experiences were reported in clinical trials (as possible adverse drug reactions in the opinion of investigating clinicians, with a frequency of ≥1%) during treatment with COSUDEX 50 mg plus an LHRH agonist. No causal relationship of these experiences to drug treatment has been made and some of the experiences reported are those that commonly occur in elderly patients.

Table 1: COSUDEX adverse drug reactions by frequency and System Organ Class

<table>
<thead>
<tr>
<th>Frequency</th>
<th>System Organ Class</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>Blood and lymphatic</td>
<td>anaemia</td>
</tr>
<tr>
<td>(≥10%)</td>
<td>Nervous system disorders</td>
<td>dizziness</td>
</tr>
<tr>
<td></td>
<td>Vascular disorder</td>
<td>hot flush</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal disorders</td>
<td>abdominal pain, constipation, nausea</td>
</tr>
<tr>
<td></td>
<td>Renal and urinary disorders</td>
<td>haematuria</td>
</tr>
<tr>
<td></td>
<td>Reproductive system and breast disorders</td>
<td>breast tenderness¹, gynaecomastia¹</td>
</tr>
<tr>
<td></td>
<td>General disorders and administration site</td>
<td>asthenia, chest pain, oedema</td>
</tr>
<tr>
<td></td>
<td>conditions</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Metabolism and nutrition disorders</td>
<td>decreased appetite</td>
</tr>
<tr>
<td>(≥1% - &lt;10%)</td>
<td>Psychiatric disorders</td>
<td>decreased libido, depression</td>
</tr>
<tr>
<td></td>
<td>Nervous system disorders</td>
<td>somnolence</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal disorders</td>
<td>dyspepsia, flatulence</td>
</tr>
<tr>
<td></td>
<td>Hepato-biliary disorders</td>
<td>hepatotoxicity, jaundice,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hypertransaminasaemia²</td>
</tr>
<tr>
<td></td>
<td>Skin and subcutaneous tissue disorders</td>
<td>alopecia, hirsuitism/ hair re-growth, rash,</td>
</tr>
<tr>
<td></td>
<td>Reproductive system and breast disorders</td>
<td>dry skin, pruritis</td>
</tr>
<tr>
<td></td>
<td>Investigations</td>
<td>erectile dysfunction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>weight increased</td>
</tr>
<tr>
<td>Frequency</td>
<td>System Organ Class</td>
<td>Event</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Uncommon (≥0.1% - &lt;1%)</td>
<td>Immune system disorders</td>
<td>hypersensitivity reactions, angioedema, and urticaria</td>
</tr>
<tr>
<td></td>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>interstitial lung disease (ILD)⁴ - fatal outcomes have been reported.</td>
</tr>
<tr>
<td>Rare (≥0.01% - &lt;0.1%)</td>
<td>Hepato-biliary disorders</td>
<td>hepatic failure⁵ - fatal outcomes have been reported.</td>
</tr>
</tbody>
</table>

¹May be reduced by concomitant castration
²Hepatic changes are rarely severe and were frequently transient, resolving or improving with continued therapy or following cessation of therapy
³Observed in a pharmaco-epidemiology study of LHRH agonists and anti-androgens used in the treatment of prostate cancer. The risk appears to be increased when COSUDEX 50 mg was used in combination with LHRH agonists but no increase in risk was evident when COSUDEX 150 mg was used as a monotherapy to treat prostate cancer.
⁴Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of interstitial pneumonia in the randomised treatment period of the 150 mg EPC studies
⁵Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of hepatic failure in patients receiving treatment in the open-label COSUDEX arm of the 150 mg EPC studies

In addition, heart failure was reported in clinical trials (as a possible adverse drug reaction in the opinion of investigating clinicians, with a frequency of >1%) during treatment with COSUDEX plus an LHRH analogue. There is no evidence of a causal relationship with drug treatment.

**DOSAGE AND ADMINISTRATION**

**ADULT MALES INCLUDING THE ELDERLY**

One tablet (50 mg) once a day.

Treatment with COSUDEX 50 mg should be started at the same time as treatment with a LHRH agonist.

**Use in adult males with renal impairment**

No dosage adjustment is necessary for patients with renal impairment.

**Use in adult males with hepatic impairment**

No dosage adjustment is necessary for patients with mild hepatic impairment.

Increased accumulation may occur in patients with moderate to severe hepatic impairment (see **PRECAUTIONS**). In such cases, a lower or less frequent dose may be considered.
OVERDOSAGE

There is no human experience of overdosage. There is no specific antidote; treatment should be symptomatic. Dialysis may not be helpful, since bicalutamide is highly protein bound and is not recovered unchanged in the urine. General supportive care, including frequent monitoring of vital signs, is indicated.

PRESENTATION AND STORAGE CONDITIONS

COSUDEX 50 mg tablets, blister pack 28 tablets.

Round, biconvex, white film-coated tablet impressed with Cdx50 on one side and an arrow shaped logo on the other side.

Storage conditions
Store below 30°C.

POISON SCHEDULE OF THE MEDICINE

Prescription only medicine (Schedule 4)

NAME AND ADDRESS OF THE SPONSOR

AstraZeneca Pty Ltd
ABN 54 009 682 311
Alma Road
NORTH RYDE NSW 2113

DATE OF APPROVAL

Date of TGA Approval: 01 July 2009
Date of most recent amendment – 24 March 2010

© AstraZeneca 2010

COSUDEX® is a trademark of the AstraZeneca group of companies